Pharmacological Activity of Natural Products in Central Nervous System Disorders
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 278
Special Issue Editors
Interests: Neuropharmacology; behavioral neuroscience; epilepsy; depression; anxiety; natural compounds
Special Issues, Collections and Topics in MDPI journals
Interests: epilepsy; antiepileptic drug
Interests: natural products chemistry; chromatography; mass spectrometry; bioactivity testing; secondary metabolites; countercurrent chromatography
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
CNS diseases are related to abnormalities in the structure and/or functioning of the brain and spinal cord that might result in a variety of neurological and psychiatric abnormalities. Possible reasons for these disorders include injuries, ischemia, inflammatory processes of nervous tissue, neurotransmission disorders, oxidative stress, etc. CNS diseases cause significant deteriorations in patients' lives and, therefore, there is a high demand to discover novel therapies and neuroprotective compounds for their prophylaxis and therapy.
Plants offer a rich variety of compounds that can be used as therapeutics also in the treatment of CNS diseases. Neuroprotective properties of a large number of these compounds have been confirmed in preclinical studies employing experimental animal models, and their mechanisms of action have been identified based on biochemical and molecular studies. Plant-derived therapeutics have been used since ancient times and they have contributed to the development of drugs used today to treat a broad range of nervous system diseases.
The main aim of the Special Issue, “Pharmacological Activity of Natural Products in Central Nervous System Disorders”, is to present novel data on the pharmacological properties of plant-derived products (i.e., extracts and their ingredients), which might have potential implications in the treatment of CNS disorders. Selected mechanisms of action of the tested products should be described in the submitted papers. Preclinical studies from in vitro tests and animal models will be considered. Submission of original papers, reviews and short communications is encouraged.
Dr. Dorota Nieoczym
Prof. Dr. Kinga Gaweł
Prof. Dr. Wirginia Kukuła-Koch
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CNS disorders
- phytochemicals
- neurotherapeutics
- neuroprotection
- neuropharmacology
- drug discovery/development
